Dr Hu Zhenyu is currently a Senior Research Fellow at the Calcium Signaling Laboratory led by Assoc Prof Liao Ping at the National Neuroscience Institute, specialising in neurodegenerative and cardiovascular diseases by modulating voltage-gated calcium channels. His research focuses on understanding the calcium channel dysfunction mediated by its functional binding proteins, such as Galectins, Filamins and deubiquitinases, in the disease models of vascular dementia, hypertension and cardiac hypertrophy, with particular emphasis on development of novel peptide-based therapeutics.

• Ph.D., Yong Loo Lin School of Medicine, National University of Singapore, 2017
• M.Sc., School of Pharmaceutical Sciences, Peking University, 2012
• ​B.Sc., School of Pharmaceutical Sciences, Peking University, 2006

• English
• Chinese

• Senior Research Fellow, National Neuroscience Institute

• NMRC OF-YIRG, 2025 - 2028
• SingHealth Duke-NUS Academic Medicine Research Grant, 2025 - 2027
• Swee Liew-Wadsworth Research Award-Concept Grant, Department of Physiology, NUS, 2014 & 2020
• Swee Liew-Wadsworth Research Publication Gold Award, Department of Physiology, NUS, 2019 & 2023
• Inaugural Singapore Ministry of Education NUSMed Post-Doctral Fellowship, 2018.01 - 2021.01
• FASEB Travel Award, The Ion Channel Regulation Conference, Lison, Portugal, 2019.07
• President’s Graduate Fellowship from National University of Singapore, 2013.01 - 2016.09

• Modulation of voltage-gated calcium channels by Galectins and deubiquitinases
• Disease models of vascular dementia, hypertension, cardiac hypertrophy and heart failure

• Liu L, Zhou Y, Liao P, Soong, TW, & Hu ZY* . Degradation of voltage-gated calcium channels: mechanisms and applications in neurological and cardiovascular diseases. Cell Communication and Signaling, 2025, 23(1), 337.
• Hu ZY*, Zhang B, Lim L et al., S-nitrosylation-mediated reduction of CaV1.2 surface expression and open probability underlies attenuated vasoconstriction induced by nitric oxide. Hypertension. 2022, 79: 2854-2866
• Zhang Z, Dalan R, Hu ZY, et al. Reactive oxygen species scavenging nanomedicine for the treatment of ischemic heart disease. Advanced Materials, 2022, 34(35): 2202169.
• Hu ZY, Li G, Wang JW, Yu DJ, Chong SY, Wang XY,  Soon JL, Liang MC, Wong YP, Huang N, Colecraft HM, Liao P, Soong TW. Regulation of blood pressure by targeting CaV1.2-Galectin-1 interactions. Circulation 2018, 138:1431
• Hu ZY, Wang J W, Yu D, et al. Aberrant splicing promotes proteasomal degradation of L-type CaV1. 2 calcium channels by competitive binding for CaVβ subunits in cardiac hypertrophy. Scientific Reports, 2016, 6(1): 35247.
• For Full List of Publications: Hu Zhenyu-Google Scholar